Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice. 2017

Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
St. Vincent's Institute, Fitzroy, Victoria, Australia.

Recent advances in immunotherapeutics have not yet changed the routine management of autoimmune type 1 diabetes. There is an opportunity to repurpose therapeutics used to treat other diseases to treat type 1 diabetes, especially when there is evidence for overlapping mechanisms. Janus kinase (JAK) 1/JAK2 inhibitors are in development or clinical use for indications including rheumatoid arthritis. There is good evidence for activation of the JAK1/JAK2 and signal transducer and activator of transcription (STAT) 1 pathway in human type 1 diabetes and in mouse models, especially in β-cells. We tested the hypothesis that using these drugs to block the JAK-STAT pathway would prevent autoimmune diabetes. The JAK1/JAK2 inhibitor AZD1480 blocked the effect of cytokines on mouse and human β-cells by inhibiting MHC class I upregulation. This prevented the direct interaction between CD8+ T cells and β-cells, and reduced immune cell infiltration into islets. NOD mice treated with AZD1480 were protected from autoimmune diabetes, and diabetes was reversed in newly diagnosed NOD mice. This provides mechanistic groundwork for repurposing clinically approved JAK1/JAK2 inhibitors for type 1 diabetes.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000949 Histocompatibility Antigens Class II Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen. Antigens, Immune Response,Class II Antigens,Class II Histocompatibility Antigen,Class II Major Histocompatibility Antigen,Ia Antigens,Ia-Like Antigen,Ia-Like Antigens,Immune Response Antigens,Immune-Associated Antigens,Immune-Response-Associated Antigens,MHC Class II Molecule,MHC II Peptide,Class II Antigen,Class II Histocompatibility Antigens,Class II MHC Proteins,Class II Major Histocompatibility Antigens,Class II Major Histocompatibility Molecules,I-A Antigen,I-A-Antigen,IA Antigen,MHC Class II Molecules,MHC II Peptides,MHC-II Molecules,Antigen, Class II,Antigen, I-A,Antigen, IA,Antigen, Ia-Like,Antigens, Class II,Antigens, Ia,Antigens, Ia-Like,Antigens, Immune-Associated,Antigens, Immune-Response-Associated,I A Antigen,II Peptide, MHC,Ia Like Antigen,Ia Like Antigens,Immune Associated Antigens,Immune Response Associated Antigens,MHC II Molecules,Molecules, MHC-II,Peptide, MHC II,Peptides, MHC II

Related Publications

Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
July 1996, Experimental animals,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
March 2023, Proceedings of the National Academy of Sciences of the United States of America,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
May 1994, The Tohoku journal of experimental medicine,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
January 1996, Journal of immunology (Baltimore, Md. : 1950),
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
January 1987, Nature,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
November 2015, Diabetes,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
October 1985, Jikken dobutsu. Experimental animals,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
June 1992, Transplantation proceedings,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
September 2020, Blood advances,
Prerak M Trivedi, and Kate L Graham, and Nicholas A Scott, and Misty R Jenkins, and Suktilang Majaw, and Robyn M Sutherland, and Stacey Fynch, and Andrew M Lew, and Christopher J Burns, and Balasubramanian Krishnamurthy, and Thomas C Brodnicki, and Stuart I Mannering, and Thomas W Kay, and Helen E Thomas
February 1998, Clinical immunology and immunopathology,
Copied contents to your clipboard!